| answer text |
<p>The Department has made no estimate of the number of National Health Service prescriptions
for cannabis-based products in which delta-9-tetrahydrocannabinol (THC) is the dominant
ingredient.</p><p> </p><p>NHS England is using extant systems to monitor use of the
newly rescheduled unlicensed cannabis-based products for medicinal use in England.
In England, these systems monitor the number of items dispensed and associated costs
in primary care and the volume of products used and associated cost in secondary care.
NHS England Controlled Drug Accountable Officers are also collecting local intelligence
in both the NHS and independent sector.</p>
|
 |
